Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Location Directory

Clinical trials in Houston, Texas

This page shows live ClinicalTrials.gov search results for Houston, Texas, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:03 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
22526
Shown on this page
12
Current sort
Recently updated
Location scope
Houston, TX
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Houston, Texas. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 721–732 of 22,526 matching trials in Houston, TX.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Institutions in Houston

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Live official records

Open in full search
Active, not recruiting Phase 3 Interventional

Effect of Olanzapine on Opioid Craving and Misuse Among Patients Receiving Opioids for Cancer-related Pain: A Pilot Double-Blind, Randomized Control Trial

NCT06200181
View directory record Official record
Conditions
Misuse, Opioid
Interventions
Olanzapine, Placebo
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 5, 2026 · Synced Nov 15, 2026, 1:03 PM EST
Active, not recruiting Phase 2 Interventional

A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)

NCT05996471
View directory record Official record
Conditions
HIV Infections
Interventions
VH3810109, Cabotegravir, Standard of care (SOC), rHuPH20
Biological · Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 70 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
43
States / cities
Birmingham, Alabama • Bakersfield, California • Los Angeles, California + 35 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2026 · Synced Nov 15, 2026, 1:03 PM EST
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK

NCT06556368
View directory record Official record
Conditions
Wet Age-related Macular Degeneration
Interventions
Tarcocimab tedromer, Tabirafusp tedromer, Aflibercept
Drug
Lead sponsor
Kodiak Sciences Inc
Industry
Eligibility
50 Years and older
Enrollment
667 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
71
States / cities
Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2026 · Synced Nov 15, 2026, 1:03 PM EST
Active, not recruiting Phase 3 Interventional Results available

Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer

NCT04269200
View directory record Official record
Conditions
Endometrial Neoplasms
Interventions
olaparib, durvalumab, durvalumab placebo, olaparib placebo, Carboplatin, Paclitaxel
Drug · Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 150 Years · Female only
Enrollment
805 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
50
States / cities
Tucson, Arizona • Concord, California • La Jolla, California + 45 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2026 · Synced Nov 15, 2026, 1:03 PM EST
Active, not recruiting No phase listed Observational

Symptomatic Carotid Outcomes Registry

NCT05300737
View directory record Official record
Conditions
Carotid Stenosis, Ischemic Stroke, Transient Ischemic Attack
Interventions
intensive medical therapy
Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
40 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
11
States / cities
Hartford, Connecticut • Atlanta, Georgia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2026 · Synced Nov 15, 2026, 1:03 PM EST
Active, not recruiting Phase 2Phase 3 Interventional Results available

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (ARTISTRY-1)

NCT05502341
View directory record Official record
Conditions
HIV-1-infection
Interventions
Bictegravir, Lenacapavir, BIC/LEN FDC, Stable Baseline Regimen
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
689 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
40
States / cities
Berkeley, California • Beverly Hills, California • Los Angeles, California + 34 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2026 · Synced Nov 15, 2026, 1:03 PM EST
Not yet recruiting Phase 3 Interventional

A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and Obesity

NCT07919405
View directory record Official record
Conditions
Hypertension, Obesity
Interventions
CagriSema, Semaglutide, Cagrilintide, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
57
States / cities
Concord, California • Costa Mesa, California • Fullerton, California + 47 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2026 · Synced Nov 15, 2026, 1:03 PM EST
Recruiting Phase 1 Interventional

Anti-GD2 ADC M3554 in Advanced Solid Tumors

NCT06641908
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
M3554
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 5, 2026 · Synced Nov 15, 2026, 1:03 PM EST
Terminated Phase 2 Interventional Results available

A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease

NCT04619420
View directory record Official record
Conditions
Alzheimer Disease, Cognitive Dysfunction, Dementia
Interventions
JNJ-63733657, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
55 Years to 80 Years
Enrollment
523 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
55
States / cities
Birmingham, Alabama • Phoenix, Arizona • Irvine, California + 47 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2026 · Synced Nov 15, 2026, 1:03 PM EST
Recruiting Not applicable Interventional

Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

NCT07214532
View directory record Official record
Conditions
Breast Neoplasms, Carcinoma, Ductal, Breast, Receptors, Estrogen (for ER-positive Requirement)
Interventions
ctDNA-Guided Treatment Strategy
Device
Lead sponsor
Natera, Inc.
Industry
Eligibility
18 Years and older
Enrollment
725 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2037
U.S. locations
50
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2026 · Synced Nov 15, 2026, 1:03 PM EST
Recruiting Phase 2 Interventional

Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System

NCT07042295
View directory record Official record
Conditions
Locally Recurrent Skin Squamous Cell Carcinoma, Metastatic Skin Squamous Cell Carcinoma
Interventions
Amivantamab and Recombinant Human Hyaluronidase, Biospecimen Collection, Cetuximab, Computed Tomography, Magnetic Resonance Imaging
Drug · Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
59
States / cities
Birmingham, Alabama • Gilbert, Arizona • La Jolla, California + 50 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2026 · Synced Nov 15, 2026, 1:03 PM EST
Recruiting Phase 3 Interventional

Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

NCT07228832
View directory record Official record
Conditions
Metastatic Colorectal Cancer (CRC)
Interventions
Drug: Ivonescimab Injection, Drug: Bevacizumab Injection
Drug
Lead sponsor
Summit Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
112
States / cities
Mobile, Alabama • Tuscaloosa, Alabama • Goodyear, Arizona + 94 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2026 · Synced Nov 15, 2026, 1:03 PM EST